BR112023002803A2 - Método de tratamento de uma doença autoimune com anticorpos monoclonais cd40 antagonísticos - Google Patents

Método de tratamento de uma doença autoimune com anticorpos monoclonais cd40 antagonísticos

Info

Publication number
BR112023002803A2
BR112023002803A2 BR112023002803A BR112023002803A BR112023002803A2 BR 112023002803 A2 BR112023002803 A2 BR 112023002803A2 BR 112023002803 A BR112023002803 A BR 112023002803A BR 112023002803 A BR112023002803 A BR 112023002803A BR 112023002803 A2 BR112023002803 A2 BR 112023002803A2
Authority
BR
Brazil
Prior art keywords
autoimmune disease
antagonistic
antibody
treatment
monoclonal antibodies
Prior art date
Application number
BR112023002803A
Other languages
English (en)
Portuguese (pt)
Inventor
Ye Ying
Aras Urvi
Sharda Nidhi
Struthers Mary
PRICE Karen
Girgis Ihab
Fura Aberra
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR112023002803A2 publication Critical patent/BR112023002803A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
BR112023002803A 2020-08-25 2021-08-25 Método de tratamento de uma doença autoimune com anticorpos monoclonais cd40 antagonísticos BR112023002803A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063070209P 2020-08-25 2020-08-25
PCT/US2021/047610 WO2022046942A1 (en) 2020-08-25 2021-08-25 Method of treating an autoimmune disease with antagonistic cd40 monoclonal antibodies

Publications (1)

Publication Number Publication Date
BR112023002803A2 true BR112023002803A2 (pt) 2023-03-14

Family

ID=77693641

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023002803A BR112023002803A2 (pt) 2020-08-25 2021-08-25 Método de tratamento de uma doença autoimune com anticorpos monoclonais cd40 antagonísticos

Country Status (11)

Country Link
US (1) US20230331860A1 (https=)
EP (1) EP4204099A1 (https=)
JP (1) JP2023539736A (https=)
KR (1) KR20230054451A (https=)
CN (1) CN116322761A (https=)
AU (1) AU2021331087A1 (https=)
BR (1) BR112023002803A2 (https=)
CA (1) CA3190727A1 (https=)
IL (1) IL300765A (https=)
MX (1) MX2023002093A (https=)
WO (1) WO2022046942A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
TWI788340B (zh) * 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
AU2018361743A1 (en) * 2017-11-03 2020-04-09 Novartis Ag Anti-CD40 antibodies for use in treatment of Sjogren's syndrome
AR117091A1 (es) * 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos

Also Published As

Publication number Publication date
AU2021331087A1 (en) 2023-04-20
CN116322761A (zh) 2023-06-23
MX2023002093A (es) 2023-03-15
JP2023539736A (ja) 2023-09-19
WO2022046942A1 (en) 2022-03-03
IL300765A (en) 2023-04-01
CA3190727A1 (en) 2022-03-03
EP4204099A1 (en) 2023-07-05
US20230331860A1 (en) 2023-10-19
KR20230054451A (ko) 2023-04-24

Similar Documents

Publication Publication Date Title
Atretkhany et al. Intrinsic TNFR2 signaling in T regulatory cells provides protection in CNS autoimmunity
Zhang et al. In vivo expansion of regulatory T cells with IL-2/IL-2 antibody complex protects against transient ischemic stroke
MX2023014985A (es) Agonista del receptor de glp-1 y composicion y uso del mismo.
WO2023122714A3 (en) Compositions and methods for treatment of thyroid eye disease
Betts et al. Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell–stimulated T cells yet preserves immunity to recall antigen
Lauder et al. Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3
DE60334364D1 (de) Behandlungsverfahren unter verwendung von anti-cd22-antikörpern
ES2188649T3 (es) Fenil-alquil-imidazoles como antagonistas del receptor h3.
WO2019147805A3 (en) Regulatory t cells targeted with chimeric antigen receptors
MX2024002467A (es) Terapias combinadas.
ES2101715T3 (es) Procedimiento de activacion de la actividad citolitica de los linfocitos utilizando anticuerpos anti-cd28.
MY204740A (en) Antagonistic cd40 monoclonal antibodies and uses thereof
WO2021016571A3 (en) Methods of treating antibody-mediated disorders with fcrn antagonists
ES2100174T3 (es) Nuevos anticuerpos reactivos con carcinomas humanos.
IL190991A (en) Causes of cardiac infarction and delay of left ventricular remodeling after cardiac infarction containing antibody that identifies IL-6 receptor as active substance
Watanabe et al. Antibody dependent cellular phagocytosis (ADCP) and antibody dependent cellular cytotoxicity (ADCC) of breast cancer cells mediated by bispecific antibody, MDX-210
DK2065467T3 (da) Anti-interferon-alfa-antistoffer
Monahan et al. Circulating T cell subsets are altered in individuals with chronic spinal cord injury
Saraceni et al. Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia
MX2021012488A (es) Receptores de antigeno quimerico del receptor 1 anti-folato humanizado y usos de los mismos.
MX2025008040A (es) Métodos para tratar el síndrome de sjögren primario con el uso de antagonistas fcrn
Lokhandwala et al. Cardiovascular dopamine receptors: role of renal dopamine and dopamine receptors in sodium excretion.
BR112023002803A2 (pt) Método de tratamento de uma doença autoimune com anticorpos monoclonais cd40 antagonísticos
MX2025003623A (es) Receptores modificados resistentes a anticuerpos para mejorar terapias basadas en celulas
EP4530295A3 (en) Fcrn antagonists and methods of use